Stocktoria
Keros Therapeutics, Inc. KROS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-04-08
Keros Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 27.7% | -5939.0% | -112543.7% | — | -280.5% |
| Net margin | 35.7% | -5277.5% | -101319.2% | — | -292.3% |
| FCF margin | 43.4% | -4585.9% | -84087.4% | — | -314.3% |
| Return on assets | 25.7% | -30.4% | -41.3% | -34.1% | -23.0% |
| Return on equity | 28.7% | -32.8% | -46.1% | -37.7% | -24.2% |
| Current ratio | 15.45 | 21.45 | 14.25 | 17.27 | 21.23 |
| Revenue growth | 6775.0% | 2251.0% | — | -100.0% | — |
Source: SEC EDGAR filings · CIK 0001664710 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.